Temenos Launches Next-Generation Front Office Suite
At the 2018 Temenos Community Forum, Temenos (SIX:TEMN), the banking software company, today launched its Temenos Front Office Suite, unleashing the full potential of digital services for banking customers across the retail, corporate and wealth segments. An open, omni-channel, data-driven solution, Temenos Front Office Suite equips banks to offer consistent, personalized and responsive digital banking journeys to their customers and prospects irrespective of the bank’s core banking solution. Temenos Front Office Suite runs on the same technology platform as its market-leading Temenos T24 Core Banking software. This enables banks to selectively augment their legacy systems with Temenos’ core banking rich functionality such as cash management, enhanced charging and interest processing.
More than 300 clients already run Temenos’ front office software including Banque Raiffeisen, Metro Bank, MyState and KBC. Temenos was cited as a Leader by top analyst houses such as Forrester1 and Ovum2 and ranked the market’s leading software provider in the digital banking and channels category in the IBS Intelligence Sales League Table 2018.
Sampath Bank, the third largest private bank in Sri Lanka and one of the most innovative banks in the Asia-Pacific region, has just selected Temenos Front Office Suite to run on a third-party core banking system, in order to offer its customers innovative products and services, especially targeted at millennials.
Temenos Front Office Suite ensures rapid time to value for banks wishing to renovate their front office irrespective of their core banking technology. Banks can implement the Temenos Front Office Suite as an independent solution or as part of a full front-to-back progressive renovation program.
Temenos Front Office Suite helps banks provide tailored advice, products and services as and when the customer requires, leading to deeper, more satisfying customer relationships yielding tangible monetary benefits such as reduced churn, improved cross-sell and revenue growth. Furthermore, Temenos with its out-of-the-box API’s, enables banks to not only comply with emerging regulations such as open banking and the Revised Payments Services Directive (PSD2), but also to aggregate third party bank data and build digital ecosystems.
Dharmesh Mistry, Chief Digital Officer, stated: “Temenos is the leader in providing upgradable, packaged banking software. With our software, banks benefit from the collective best practices of our 3000 customers, and 20% investment of our revenues in R&D, the highest in the industry. We believe that banks can only become truly digital when they transform their operations front-to-back and we are the best provider to help them realize their digital vision with our combined Front Office Suite and core banking capability on the same technology platform. However, many banks want deeper customer intimacy as an immediate benefit. Temenos Front Office Suite will help us address the needs of these banks – we estimate a total market potential of 3.2bn USD3 for banking channels and front-office third party software globally.”
Jost Hoppermann, Vice President and Principal Analyst, Forrester, wrote in The Forrester Wave™: Digital Banking Engagement Platforms, Q3 2017: “Temenos stands out with broad and rich banking capabilities…Temenos is a good fit if you are looking for broad banking capabilities with good channel support, rich analytics, a solid apps builder…”
In conclusion, Temenos Front Office Suite combines Temenos Channels, Front-Office, Analytics and Risk and Compliance, incorporating real-time event-based marketing and AI capability. Furthermore, it includes the recently launched Temenos Origination solution, for frictionless customer onboarding and product origination across all channels. The Suite is available on premise and as well as Software as a Service on Temenos Cloud.
– Ends –
Temenos Group AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 firms across the globe, including 41 of the top 50 banks, rely on Temenos to process the daily transactions of more than 500 million banking customers. Temenos customers are proven to be more profitable than their peers: over a seven-year period, they enjoyed on average a 31% higher return on assets, a 36% higher return on equity and an 8.6 percentage point lower cost/income ratio than banks running legacy applications. For more information please visit www.temenos.com.
2 Ovum Decision Matrix for Digital Banking Platforms
3 Temenos estimates based on Gartner, IDC, Celent, Ovum data
Temenos Global Public Relations Manager
Tel: +1 610 232 2793
Email : email@example.com
Newgate Communications on behalf of Temenos
Alistair Kellie & Andrew Adie
Tel: +44 20 7680 6550
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CEST | Press release
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu